安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited
- Lorundrostat Shows Promise for Resistant Hypertension
Lorundrostat acts by directly inhibiting aldosterone synthesis while sparing other adrenal steroid pathways, potentially overcoming limitations of mineralocorticoid receptor antagonists such as compensatory aldosterone elevation and poor tolerability Investigators highlighted the drug’s potential to expand therapeutic options for patients
- Lorundrostat Lowers Blood Pressure Compared with Placebo at 12 Weeks
Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC 25)
- Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled . . .
Decreasing aldosterone production via inhibition of aldosterone synthase, rather than blocking the mineralocorticoid receptor, may avoid these adverse effects Lorundrostat is a selective inhibitor of aldosterone synthase currently under investigation
- Lorundrostat - Wikipedia
Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure
- Clinical Trial Shows Drug Developed to Treat Uncontrolled Hypertension . . .
Findings from a clinical trial led by a Cleveland Clinic cardiologist showed that lorundrostat – a new type of blood pressure medication — safely decreased blood pressure in patients with uncontrolled hypertension
- Lorundrostat Safely Lowers Blood Pressure in Uncontrolled Hypertension . . .
Lorundrostat (MLS-101) ― an investigational medication that works by lowering aldosterone production ― safely and effectively lowered blood pressure (BP) in patients with hypertension refractory to standard medical treatment
- Mineralys Therapeutics Announces Positive Topline Results from Phase 2 . . .
About Lorundrostat Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uHTN or rHTN, as well as CKD and OSA Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production
|
|
|